The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Potential biomarkers of pembrolizumab response after HiDAC in R/R AML
The outcome remain somewhat poor for patients with relapsed/refractory acute myeloid leukemia (AML). Here, Joshua Zeidner, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, introduces the Phase II trial (NCT02768792) aiming to stimulate a T-cell mediated anti-leukemic immune response using pembrolizumab, a monoclonal antibody that targets the programmed death-1 (PD-1) protein, after high-dose cytarabine (HiDAC) salvage chemotherapy. Dr Zeider discusses how pembrolizumab is well tolerated after HiDAC, with an encouraging response rate observed in a high-risk patient population without apparent additive toxicity.
